Drug Trial Radar · NCT00771199
An Efficacy and Safety Study of Low-dose Transdermal Therapeutic System (TTS)-Fentanyl D-Trans in Taiwan Participants With Cancer Pain
Last checked: Nov 20, 2026Latest source record: Jun 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
14
Actual
Start
Oct 1, 2008
Primary completion
Nov 26, 2008
Study completion Nov 26, 2008
Sponsor
- Lead sponsor
- Janssen-Cilag Ltd.Johnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Oct 13, 2008
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate safety/tolerability and clinical utility of low-dose transdermal therapeutic system (TTS \[medicated adhesive pad that is placed on the skin to deliver a timed-release dose of medication through the skin into the bloodstream\]) - fentanyl in Taiwan participants with cancer pain. Secondly, to demonstrate the dropout rate that will be decreased by initiating therapy with12 microgram per hour (mcg/hr) instead of with 25 mcg/h.
Conditions
- Cancer, Pain
Interventions
Transdermal Therapeutic System (TTS)-FentanylDrug
Participants will receive 1 transdermal patch of TTS-fentanyl containing 12 micrograms per hour (mcg/h) for 28 days. Dose can be increased or decreased as per Investigator's discretion up to 100 mcg/h.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Dropped From Study due to Adverse EventsTime frame: Day 0 up to Day 28
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Janssen-Cilag Ltd.
High Wycombe, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.